Support women in science at Burnet Institute
Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Determining the role of vaginal microbiota metabolites in activating HIV and other STIs, and their immune modulatory effects on cells found in the lower female reproductive tract.
Globally, almost 19 per cent of the 1.8 million new HIV infections in 2017 were in adolescent girls and young women in sub-Saharan Africa, where the virus mainly establishes infection by entry through the cervicovagina.
Women colonised with optimal cervicovaginal microbiota, typically dominated by Lactobacillus spp., are protected against HIV in contrast to women with “non-optimal” vaginal bacteria (e.g. bacterial vaginosis (BV)). Distinguishing features between women with BV vs Lactobacillus spp. dominated cervicovaginal microbiota include a dramatic increase in vaginal pH and a change in the concentrations of the vaginal microbiota metabolites, lactic acid, short chain fatty acid (SCFAs) and succinic acid.
This study aims to determine the antiviral and immune modulatory effects of these organic acid metabolites to understand their role in either helping to protect or to promote acquisition of HIV and other STIs.
2016 – ongoing
Dr Muriel Aldunate Dr Anna Hearps Professor Deborah Anderson Dr Joshua Hayward Associate Professor Catriona Bradshaw Dr Raffi Gugasyan
NHMRC
For any general enquiries relating to this project, please contact:
Head of Life Sciences; Head of Tachedjian Laboratory (Retroviral Biology and Antivirals)